Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | SR-8541A |
Synonyms | |
Therapy Description |
SR-8541A inhibits ENPP1, leading to the activation of the STING pathway and potentially resulting in enhanced immune response and tumor growth inhibition (Cancer Res (2023) 83 (8_Supplement): LB323). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SR-8541A | SR-8541A inhibits ENPP1, leading to the activation of the STING pathway and potentially resulting in enhanced immune response and tumor growth inhibition (Cancer Res (2023) 83 (8_Supplement): LB323). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06063681 | Phase I | SR-8541A | A Study of SR-8541A (ENPPI Inhibitor) in Advanced/Metastatic Solid Tumors | Recruiting | AUS | 0 |